Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4
Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients develo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | The Breast Journal |
| Online Access: | http://dx.doi.org/10.1155/2023/2875972 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850211718273171456 |
|---|---|
| author | Meng Zhang Mei Wang Zhiming Jiang Ziyi Fu Jingjing Ma Sheng Gao |
| author_facet | Meng Zhang Mei Wang Zhiming Jiang Ziyi Fu Jingjing Ma Sheng Gao |
| author_sort | Meng Zhang |
| collection | DOAJ |
| description | Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients developed resistance to tamoxifen treatment, which reduced therapeutic efficiency and caused substandard prognosis. Therefore, the exploration of the molecular processes involved in tamoxifen resistance (TR) is urgently required. This investigation aimed to elucidate the relationship of microRNA-330 (miR-330-3p) with the TR of BC. There is little information on miR-330-3p′s link with drug-resistant BC, although it is well known to regulate cell proliferation and apoptosis. Primarily, miR-330-3p expression in parental BC (MCF7/T47D), TR (MCF7-TR), and T47D/TR cell lines was detected by qRT-PCR. Then, the impact of miR-330-3p on the TR of BC cells was assessed by a cell proliferation assay. Lastly, dual-luciferase reporter, qRT-PCR, and western blot assessments were carried out to identify histone deacetylase 4 (HDAC4) as the potential miR-330-3p target gene. The data indicated that miRNA-330 was overexpressed in TR ER+ BC cells and its overexpression could induce TR. Furthermore, miRNA-330 could also reduce the expression of HDAC4, which is closely linked to TR, and overexpression of HDAC4 could reverse miRNA-330-induced drug resistance. In summary, miR-330-3p could induce TR of ER+ BC cells by downregulating HDAC4 expression, which might be a novel marker of TR and a possible treatment target against BC patients who are tamoxifen-resistant. |
| format | Article |
| id | doaj-art-901ee3c7130e4e8c99f9988b49003a2a |
| institution | OA Journals |
| issn | 1524-4741 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Breast Journal |
| spelling | doaj-art-901ee3c7130e4e8c99f9988b49003a2a2025-08-20T02:09:30ZengWileyThe Breast Journal1524-47412023-01-01202310.1155/2023/2875972Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4Meng Zhang0Mei Wang1Zhiming Jiang2Ziyi Fu3Jingjing Ma4Sheng Gao5Division of Breast SurgeryDepartment of PathologyDepartment of Ultrasound MedicineDepartment of Breast Disease Research CenterDivision of Breast SurgeryNanjing Maternal and Child Health InstituteTamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients developed resistance to tamoxifen treatment, which reduced therapeutic efficiency and caused substandard prognosis. Therefore, the exploration of the molecular processes involved in tamoxifen resistance (TR) is urgently required. This investigation aimed to elucidate the relationship of microRNA-330 (miR-330-3p) with the TR of BC. There is little information on miR-330-3p′s link with drug-resistant BC, although it is well known to regulate cell proliferation and apoptosis. Primarily, miR-330-3p expression in parental BC (MCF7/T47D), TR (MCF7-TR), and T47D/TR cell lines was detected by qRT-PCR. Then, the impact of miR-330-3p on the TR of BC cells was assessed by a cell proliferation assay. Lastly, dual-luciferase reporter, qRT-PCR, and western blot assessments were carried out to identify histone deacetylase 4 (HDAC4) as the potential miR-330-3p target gene. The data indicated that miRNA-330 was overexpressed in TR ER+ BC cells and its overexpression could induce TR. Furthermore, miRNA-330 could also reduce the expression of HDAC4, which is closely linked to TR, and overexpression of HDAC4 could reverse miRNA-330-induced drug resistance. In summary, miR-330-3p could induce TR of ER+ BC cells by downregulating HDAC4 expression, which might be a novel marker of TR and a possible treatment target against BC patients who are tamoxifen-resistant.http://dx.doi.org/10.1155/2023/2875972 |
| spellingShingle | Meng Zhang Mei Wang Zhiming Jiang Ziyi Fu Jingjing Ma Sheng Gao Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4 The Breast Journal |
| title | Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4 |
| title_full | Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4 |
| title_fullStr | Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4 |
| title_full_unstemmed | Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4 |
| title_short | Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4 |
| title_sort | candidate oligo therapeutic target mir 330 3p induces tamoxifen resistance in estrogen receptor positive breast cancer cells via hdac4 |
| url | http://dx.doi.org/10.1155/2023/2875972 |
| work_keys_str_mv | AT mengzhang candidateoligotherapeutictargetmir3303pinducestamoxifenresistanceinestrogenreceptorpositivebreastcancercellsviahdac4 AT meiwang candidateoligotherapeutictargetmir3303pinducestamoxifenresistanceinestrogenreceptorpositivebreastcancercellsviahdac4 AT zhimingjiang candidateoligotherapeutictargetmir3303pinducestamoxifenresistanceinestrogenreceptorpositivebreastcancercellsviahdac4 AT ziyifu candidateoligotherapeutictargetmir3303pinducestamoxifenresistanceinestrogenreceptorpositivebreastcancercellsviahdac4 AT jingjingma candidateoligotherapeutictargetmir3303pinducestamoxifenresistanceinestrogenreceptorpositivebreastcancercellsviahdac4 AT shenggao candidateoligotherapeutictargetmir3303pinducestamoxifenresistanceinestrogenreceptorpositivebreastcancercellsviahdac4 |